

# New-onset postoperative atrial fibrillation after coronary artery bypass graft surgery

Mesut Engin<sup>1</sup>, Ufuk Aydın<sup>1</sup>, Gamze Cebeci<sup>2</sup>, Yusuf Ata<sup>1</sup>

<sup>1</sup>Department of Cardiovascular Surgery, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Mimar Sinan Town, Yıldırım, Bursa, Turkey

<sup>2</sup>Department of Nursing, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey

**Correspondence to:**

Mesut Engin, MD,  
Department of Cardiovascular  
Surgery, University of Health  
Sciences,  
Bursa Yuksek Ihtisas Training and  
Research Hospital,  
Emniyet Street, Yıldırım, Bursa,  
Turkey,  
phone: +90 224 295 50 00,  
e-mail:  
mesut\_kvc\_cor@hotmail.com

Copyright by the Author(s), 2022

DOI: 10.33963/KPa2022.0149

**Received:**

June 17, 2022

**Accepted:**

June 22, 2022

**Early publication date:**

June 22, 2022

We have read with great interest the article by Smukowska-Gorynia et al. [1], entitled "Neopterin as a predictive biomarker of postoperative atrial fibrillation following coronary artery bypass grafting". First of all, we congratulate the authors for their valuable contribution to the literature. However, we would like to discuss some points about inflammatory biomarkers and postoperative atrial fibrillation (PoAF) after coronary artery bypass graft (CABG) operations.

This is a well-designed single-center study. And the reliability of the diagnosis of PoAF, which is a very important in PoAF studies, has been resolved by continuous telemetry follow-up in patients. In addition, patients who underwent elective surgery were included in the study, and patients with a history of atrial fibrillation or flutter were excluded [1]. In this study, which included prospectively planned elective surgery patients, was telemetry recording of at least 24 hours performed in the preoperative period? Could patients with preoperative atrial fibrillation have been missed?

Negative effects of thyroid dysfunctions on cardiac surgical operations are known [2]. In the current study, while patients with preoperative hyperthyroidism were excluded, a total of 10 patients with hypothyroidism were included in the study [1]. Why did the authors not exclude patients with hypothyroidism from the study? Low levels of the active thyroid hormone triiodothyronine are known to be associated with poor outcomes in cardiac surgery patients. The positive effects of triiodothyronine replacement therapy on clinical outcomes have been demonstrated in this group of patients [3].

In the current study, the authors investigated the role of the biological marker neopterin in predicting the risk of PoAF after isolated CABG operations. And neopterin blood levels were measured at three different times (before operation, on the 1st day after operation, and between the fifth and eighth day after operation). PoAF is frequently detected in the first five days after the operation and peaks on the second day [4]. Why did the authors measure neopterin between the fifth and eighth days of their study? Did they intend to predict the recurrence of PoAF? The recurrence of PoAF was detected in 10 patients in their study [1].

In their study, the authors stated that the multivariable models were divided into three models: preoperative (5 variables), surgical (2 variables), and echocardiographic (5 variables). Here, the patient groups were determined as 30 patients who developed PoAF and 71 patients who did not [1]. In two multivariable models, five variables were included in the analysis. Could this be the cause of overfitting [5]?

## Article information

**Conflict of interest:** None declared.

**Funding:** None.

**Open access:** This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at [kardiologiapolska@ptkardio.pl](mailto:kardiologiapolska@ptkardio.pl).

## REFERENCES

1. Smukowska-Gorynia A, Perek B, Jemielity M, et al. Neopterin as a predictive biomarker of postoperative atrial fibrillation following coronary artery bypass grafting. *Kardiol Pol.* 2022, 80(9): 910–910, doi: [10.33963/KP.a2022.0143](https://doi.org/10.33963/KP.a2022.0143), indexed in Pubmed: [35698968](https://pubmed.ncbi.nlm.nih.gov/35698968/).
2. Zhao D, Xu F, Yuan X, et al. Impact of subclinical hypothyroidism on outcomes of coronary bypass surgery. *J Card Surg.* 2021; 36(4): 1431–1438, doi: [10.1111/jocs.15395](https://doi.org/10.1111/jocs.15395), indexed in Pubmed: [33567099](https://pubmed.ncbi.nlm.nih.gov/33567099/).
3. Tharmapooopathy M, Thavarajah A, Kenny RPW, et al. Efficacy and Safety of Triiodothyronine Treatment in Cardiac Surgery or Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Thyroid.* 2022 [Epub ahead of print], doi: [10.1089/thy.2021.0609](https://doi.org/10.1089/thy.2021.0609), indexed in Pubmed: [35403448](https://pubmed.ncbi.nlm.nih.gov/35403448/).
4. Filardo G, Damiano RJ, Ailawadi G, et al. Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. *Heart.* 2018; 104(12): 985–992, doi: [10.1136/heartjnl-2017-312150](https://doi.org/10.1136/heartjnl-2017-312150), indexed in Pubmed: [29326112](https://pubmed.ncbi.nlm.nih.gov/29326112/).
5. Shi L, Westerhuis JA, Rosén J, et al. Variable selection and validation in multivariate modelling. *Bioinformatics.* 2019; 35(6): 972–980, doi: [10.1093/bioinformatics/bty710](https://doi.org/10.1093/bioinformatics/bty710), indexed in Pubmed: [30165467](https://pubmed.ncbi.nlm.nih.gov/30165467/).